Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Gains from Investment Securities (2019 - 2025)

Historic Gains from Investment Securities for aTYR PHARMA (ATYR) over the last 6 years, with Q3 2025 value amounting to $136000.0.

  • aTYR PHARMA's Gains from Investment Securities rose 880.0% to $136000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $528000.0, marking a year-over-year increase of 11204.82%. This contributed to the annual value of $497000.0 for FY2024, which is 7319.31% down from last year.
  • According to the latest figures from Q3 2025, aTYR PHARMA's Gains from Investment Securities is $136000.0, which was up 880.0% from $133000.0 recorded in Q2 2025.
  • aTYR PHARMA's Gains from Investment Securities' 5-year high stood at $7.9 million during Q4 2022, with a 5-year trough of -$120000.0 in Q4 2023.
  • Over the past 4 years, aTYR PHARMA's median Gains from Investment Securities value was $131000.0 (recorded in 2025), while the average stood at $763066.7.
  • Over the last 5 years, aTYR PHARMA's Gains from Investment Securities had its largest YoY gain of 107191.01% in 2023, and its largest YoY loss of 10151.99% in 2023.
  • aTYR PHARMA's Gains from Investment Securities (Quarter) stood at $7.9 million in 2022, then plummeted by 101.52% to -$120000.0 in 2023, then soared by 206.67% to $128000.0 in 2024, then rose by 6.25% to $136000.0 in 2025.
  • Its last three reported values are $136000.0 in Q3 2025, $133000.0 for Q2 2025, and $131000.0 during Q1 2025.